ClinicalTrials.gg
CompletedNCT07354516FirecrestUpdated Jul 29, 2026

Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension

A Phase 2/3 interventional study of QLS-111-FDC and Latanoprost (0.005%) in OAG - Open-Angle Glaucoma and OHT - Ocular Hypertension, sponsored by Qlaris Bio, Inc.. Completed at 1 site in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-07-29.

Sponsored by Qlaris Bio, Inc. · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 348 studies in Glaucoma, Open-Angle with a site in United States — 49 open to participants now, 67 under way, 5 of them phase 3. Glaucoma, Open-Angle · United States.

Enrollment
166th of 279
64 · median 84
Started
2026
with 18 others
Phase 2/3
5 of 348
none open now
Registered
334th of 348
by date

Among the 348 studies in Glaucoma, Open-Angle with a site in United States, this one is the 166th largest by enrollment of the 279 interventional ones that give a count, is one of 19 that started in 2026, is one of 5 in phase 2/3, and was the 334th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 116 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

49 of the 348 studies in Glaucoma, Open-Angle with a site in United States are open now. Recruiting first, the newest first:

44 more — sign in →

All 49 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 83 Glaucoma, Open-Angle studies recruiting now, 64 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 348 studies in Glaucoma, Open-Angle with a site in United States, or all of them as a file.
02

Study summary

Firecrest study is evaluating the intraocular pressure (IOP)-lowering effect, safety, and tolerability of Qlaris' preservative free [PF], fixed-dose combination [FDC] investigational product (IP) in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).

Read the detailed description

14-day prospective, double-masked, active-controlled, randomized multicenter study comparing QLS-111-FDC and PF latanoprost. Study is comprised of 5 visits.

03

Conditions studied

  • OAG - Open-Angle Glaucoma
  • OHT - Ocular Hypertension

Keywords

  • glaucoma
  • intraocular pressure (IOP)
  • eye drops
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • BCVA 1.0 logMAR or better in each eye (equivalent to 20/200)
  • Diagnosis of mild to moderate OAG or OHT in at least one eye
  • IOP ≥19 mmHg at 08:00 hour (H) at Qualification Visits following a run-in with PF latanoprost

Exclusion criteria

Exclusion Criteria:

  • History of active ocular disease other than mild to moderate OAG/OHT
  • Prior use of any topical PGA without a response
  • Noncompliant with current ocular anti-hypertensive medications or unwilling to be compliant throughout the study
  • Use of other topical ocular concomitant medications 30 days prior
  • History of angle closure or a narrow angle, significant ocular trauma, ocular infection, uveitis, intraocular surgery in either eye.
  • Central corneal thickness in either eye \<470 or >630 μm
  • Clinically significant systemic or psychiatric disease, chronic kidney disease, or hypertension, hypotension, or diabetes that is uncontrolled.
  • Participation in any study within 30 days prior to Screening
  • Females who are pregnant, nursing, or not using .
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    QLS-111-FDC ophthalmic solution

    QLS-111-FDC, PF FDC

    Combination Product: QLS-111-FDC

  • Active comparator
    Latanoprost ophthalmic solution

    PF latanoprost 0.005%

    Drug: Latanoprost (0.005%)

Interventions

  • Combination productQLS-111-FDC

    QLS-111-FDC, a PF FDC administered by topical ophthalmic (TO) application for 14 days in the evening (QPM) in both eyes (OU).

  • PF latanoprost administered by TO application for 14 days QPM OU.

    Also known as: latanoprost ophthalmic solution 0.005%, PF

06

What researchers measure

Primary outcomes

  1. Change from baseline in IOP

    Change from baseline in IOP, lowering of IOP compared to baseline is desirable outcome.

    Time frame: Over 15 days

Secondary outcomes

  1. Ocular safety and tolerability

    Incidence of ocular adverse events

    Time frame: Over 15 days

  2. Ocular comfort

    Ocular comfort following study treatment as assessed by subject and using a visual analog scale (VAS) provided by the site at the treatment period visits. Subjects will grade their ocular comfort on a scale of 0 (extremely comfortable) to 100 (extremely uncomfortable) by placing a vertical mark on the horizontal line.

    Time frame: Over 15 days

07

Study locations

1 site
  • Shettle Eye Research
    Largo, Florida 33773, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2026 to primary completion in Jul 2026, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2026
First posted
Jan 21, 2026
StartActual
Mar 18, 2026
Primary completionActual
Jul 22, 2026
CompletionActual
Jul 22, 2026
Last update
Jul 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07354516
Lead sponsor
Qlaris Bio, Inc.
Responsible party
Sponsor
First posted
Jan 21, 2026
Start date
Mar 18, 2026
Primary completion
Jul 22, 2026
Completion
Jul 22, 2026
Last update
Jul 29, 2026

Study contacts

Barbara M Wirostko, MD
study director · Qlaris Bio, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: QLS-111

Start the discussion